Genetic testing for neurodegenerative diseases: Ethical and health communication challenges
J. Scott Roberts, Anne K. Patterson, Wendy R. Uhlmann
Neurobiology of Disease · 2020
doi:10.1016/j.nbd.2020.104871 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Advances in genomic science are informing an expansion of genetic testing for neurodegenerative diseases, which can be used for diagnostic and predictive purposes and performed in both medical and consumer genomics settings. Such testing—which is often for severe and incurable conditions like Huntington's, Alzheimer's, and Parkinson's diseases—raises important ethical and health communication challenges. This review addresses such challenges in the contexts of clinical, research, and direct-to-consumer genetic testing; these include informed consent, risk estimation and communication, potential benefits and psychosocial harms of genetic information (e.g., genetic discrimination), access to services, education and workforce needs, and health policies. The review also highlights future areas of likely growth in the field, including polygenic risk scores, use of genetic testing in clinical trials, and return of individual research results.
Abstract licence: CC BY-NC
Cited by papers we hold2
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.